Radiotherapy is often used palliatively in patients with metastatic lung cancer in the interest of achieving a better quality of life. But whether survival after palliative radiation justifies using the modality is debatable. Clinicians from Louisiana shed some light on the issue with a study that looked at prognostic factors in lung cancer with brain metastases. Would these patients be better off with hospice or supportive care?
RESULT: Short survival after palliative radiotherapy for brain metastases in lung cancer: Does the end justify the means?
American Journal of Hospice & Palliative Medicine | Jun 9, 2013 (Free abstract. Full text $32)
Chemoradiotherapy has become a go-to in cancer treatment, but this pairing is not always successful. One group of researchers tested the regimen of stereotactic radiosurgery, whole-brain radiation, temozolomide(Drug information on temozolomide) (Temodar), and erlotinib (Tarceva) in non-small cell lung cancer patients with brain metastases. They describe their trial results and explain why they were less than pleased with survival outcomes.
RESULT: A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320
International Journal of Radiation Oncology, Biology, Physics (PubMed) | Apr 1, 2013 (Free abstract. Full text $30)